Journal of Clinical Investigation · 2005 · 953 citations · 44 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyEffector T Cell FunctionT Cell ActivationT Cell BiologyT Cell Responses To TumorsAdoptive ImmunotherapyCd8 Positive T CellsCd8+ Tumor-infiltrating LymphocytesCell ActivationEffector T Cell DifferentiationHomeostatic CytokinesT Cell-based ImmunotherapyT Cell-mediated Tumor Killing
T cell differentiation is a progressive process marked by phenotypic and functional changes, yet terminal effector cells lose lymphoid‑homing, IL‑2 production, and proliferative capacity, leading to impaired in vivo antitumor activity. The study evaluated the adoptive immunotherapy efficacy of tumor‑specific CD8+ T cells at different differentiation stages by transferring them into tumor‑bearing mice. Tumor‑specific CD8+ T cells at multiple differentiation stages were adoptively transferred into tumor‑bearing mice to assess therapeutic efficacy.
T cell differentiation is a progressive process characterized by phenotypic and functional changes. By transferring tumor-specific CD8+ T cells into tumor-bearing mice at various stages of differentiation, we evaluated their efficacy for adoptive immunotherapy. We found that administration of naive and early effector T cells, in combination with active immunization and IL-2, resulted in the eradication of large, established tumors. Despite enhanced in vitro antitumor properties, more-differentiated effector T cells were less effective for in vivo tumor treatment. Several events may underlie this paradoxical phenomenon: (a) downregulation of lymphoid-homing and costimulatory molecules; (b) inability to produce IL-2 and access homeostatic cytokines; and (c) entry into a proapoptotic and replicative senescent state. While the progressive acquisition of terminal effector properties is characterized by pronounced in vitro tumor killing, in vivo T cell activation, proliferation, and survival are progressively impaired. These findings suggest that the current methodology for selecting T cells for transfer is inadequate and provide new criteria for the generation and the screening of optimal lymphocyte populations for adoptive immunotherapy.
44
Cancer immunotherapy: moving beyond current vaccines
Steven A. Rosenberg, James C. Yang, Nicholas P. Restifo · Nature Medicine · 2004 · 3K citations · Full text
Medicine, Immunology, Oncology +14
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley, John R. Wunderlich, Paul F. Robbins et al. · Science · 2002 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +17
Lineage relationship and protective immunity of memory CD8 T cell subsets
E. John Wherry, Volker Teichgräber, Todd C. Becker et al. · Nature Immunology · 2003 · 1.8K citations
Elizabeth Walter, Philip D. Greenberg, M. Jean Gilbert et al. · New England Journal of Medicine · 1995 · 1.8K citations